Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd reports that their Phase I/II clinical trial of NTI164, a broad-spectrum cannabinoid drug therapy, has successfully reached a two-year milestone without any serious adverse events in treating Autism Spectrum Disorder (ASD) patients. The results showcase NTI164’s potential as a long-term therapy option for autism, with continued clinical improvements and no treatment drop-outs. The company highlights the significant commercial opportunity in developing NTI164, given the lack of safe and effective treatments for several neurological disorders.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
